142 related articles for article (PubMed ID: 9476060)
1. Cancer of the uterine cervix: sensitivity and specificity of serum Cyfra 21.1 determinations.
Callet N; Cohen-Solal Le Nir CC; Berthelot E; Pichon MF
Eur J Gynaecol Oncol; 1998; 19(1):50-6. PubMed ID: 9476060
[TBL] [Abstract][Full Text] [Related]
2. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer.
Kainz C; Sliutz G; Mustafa G; Bieglmayr C; Koelbl H; Reinthaller A; Gitsch G
Gynecol Oncol; 1995 Mar; 56(3):402-5. PubMed ID: 7535720
[TBL] [Abstract][Full Text] [Related]
3. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
4. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
5. Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen.
Tsai SC; Kao CH; Wang SJ
Neoplasma; 1996; 43(1):27-9. PubMed ID: 8843956
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.
Banal A; Hacene K; Berthelot-Ruff E; Mahé E; Fontana X; Pichon MF
Tumour Biol; 2001; 22(1):27-35. PubMed ID: 11054024
[TBL] [Abstract][Full Text] [Related]
7. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.
Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R
Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543
[TBL] [Abstract][Full Text] [Related]
8. Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment.
Pras E; Willemse PH; Canrinus AA; de Bruijn HW; Sluiter WJ; ten Hoor KA; Aalders JG; Szabo BG; de Vries EG
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):23-32. PubMed ID: 11777619
[TBL] [Abstract][Full Text] [Related]
9. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy.
Suzuki Y; Nakano T; Ohno T; Abe A; Morita S; Tsujii H
J Cancer Res Clin Oncol; 2000 Jun; 126(6):332-6. PubMed ID: 10870643
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
11. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma.
Lee JK; Hsieh JF; Tsai SC; Ho YJ; Sun SS; Kao CH
Ann Otol Rhinol Laryngol; 2001 Aug; 110(8):775-8. PubMed ID: 11510737
[TBL] [Abstract][Full Text] [Related]
12. [Investigation of the usefulness of CYFRA 21-1 as a tumor marker in squamous cell carcinomas of the head and neck].
Sano K; Kataoka S; Katoh T; Kawauchi H; Morikawa S
Nihon Jibiinkoka Gakkai Kaiho; 1997 Jul; 100(7):790-7. PubMed ID: 9277101
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA.
Molina R; Filella X; Augé JM; Bosch E; Torne A; Pahisa J; Lejarcegui JA; Rovirosa A; Mellado B; Ordi J; Biete A
Anticancer Res; 2005; 25(3A):1765-71. PubMed ID: 16033097
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1.
Pradier O; Hille A; Schmiberger H; Hess CF
Cancer Radiother; 2002 Feb; 6(1):15-21. PubMed ID: 11899676
[TBL] [Abstract][Full Text] [Related]
16. Significance of elevated SCC-Ag level on tumor recurrence and patient survival in patients with squamous-cell carcinoma of uterine cervix following definitive chemoradiotherapy: a multi-institutional analysis.
Choi KH; Lee SW; Yu M; Jeong S; Lee JW; Lee JH
J Gynecol Oncol; 2019 Jan; 30(1):e1. PubMed ID: 30479085
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis.
Pastor A; Menéndez R; Cremades MJ; Pastor V; Llopis R; Aznar J
Eur Respir J; 1997 Mar; 10(3):603-9. PubMed ID: 9072992
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of cytokeratin 19 fragments in cervical cancer.
Nasu K; Etoh Y; Yoshimatsu J; Matsu T; Narahara H; Miyakawa I
Gynecol Obstet Invest; 1996; 42(4):267-70. PubMed ID: 8979101
[TBL] [Abstract][Full Text] [Related]
19. The assessment of the prognostic value of tumor markers and cytokines as SCCAg, CYFRA 21.1, IL-6, VEGF and sTNF receptors in patients with squamous cell cervical cancer, particularly with early stage of the disease.
Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Bidzinski M; Kowalska M
Tumour Biol; 2016 Jan; 37(1):1271-8. PubMed ID: 26289850
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
